The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's (HKG:6855) olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.
The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.
The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.